Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours.

Mendoza J, Martínez J, Hernández C, Pérez-Montiel D, Castro C, Fabián-Morales E, Santibáñez M, González-Barrios R, Díaz-Chávez J, Andonegui MA, Reynoso N, Oñate LF, Jiménez MA, Núñez M, Dyer R, Herrera LA.

Br J Cancer. 2013 Jul 9;109(1):68-75. doi: 10.1038/bjc.2013.303. Epub 2013 Jun 27.

2.

XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.

Cummings M, Higginbottom K, McGurk CJ, Wong OG, Köberle B, Oliver RT, Masters JR.

Biochem Pharmacol. 2006 Jul 14;72(2):166-75. Epub 2006 May 4.

PMID:
16756962
3.

Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression.

Usanova S, Piée-Staffa A, Sied U, Thomale J, Schneider A, Kaina B, Köberle B.

Mol Cancer. 2010 Sep 16;9:248. doi: 10.1186/1476-4598-9-248.

4.

Influence of genetic markers on survival in non-small cell lung cancer.

Rosell R, Taron M, Camps C, López-Vivanco G.

Drugs Today (Barc). 2003 Oct;39(10):775-86. Review.

PMID:
14668933
5.

Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.

Takenaka T, Yano T, Kiyohara C, Miura N, Kouso H, Ohba T, Kometani T, Shoji F, Yoshino I, Maehara Y.

Lung Cancer. 2010 Jan;67(1):101-7. doi: 10.1016/j.lungcan.2009.03.007. Epub .

PMID:
19361884
6.

Regulation of DNA repair gene expression in human cancer cell lines.

McGurk CJ, Cummings M, Köberle B, Hartley JA, Oliver RT, Masters JR.

J Cell Biochem. 2006 Apr 1;97(5):1121-36.

PMID:
16315315
7.

[Testicular cancer - explanatory models for high cisplatin chemosensibility and new therapeutic options].

Ebbing J, Christoph F, Kempkensteffen C, Weikert S, Schostak M, Hinz S, Lein M, Miller K, Schrader M.

Aktuelle Urol. 2008 Nov;39(6):429-35. doi: 10.1055/s-2008-1038284. Epub 2008 Oct 31. Review. German.

PMID:
18979397
8.

Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.

Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS.

Lung Cancer. 2004 Jun;44(3):311-6.

PMID:
15140544
9.

Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients.

Lai TC, Chow KC, Fang HY, Cho HC, Chen CY, Lin TY, Chiang IP, Ho SP.

Oncol Rep. 2011 May;25(5):1243-51. doi: 10.3892/or.2011.1184. Epub 2011 Feb 14.

PMID:
21327329
10.

Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.

Cavallo F, Graziani G, Antinozzi C, Feldman DR, Houldsworth J, Bosl GJ, Chaganti RS, Moynahan ME, Jasin M, Barchi M.

PLoS One. 2012;7(12):e51563. doi: 10.1371/journal.pone.0051563. Epub 2012 Dec 12.

11.

Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, Di Marsico R, Antonuzzo A, Orlandini C, Ricciardi S, Del Tacca M, Peters GJ, Falcone A, Danesi R.

Clin Cancer Res. 2008 Mar 15;14(6):1797-803. doi: 10.1158/1078-0432.CCR-07-1364.

12.

Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours.

Köberle B, Masters JR, Hartley JA, Wood RD.

Curr Biol. 1999 Mar 11;9(5):273-6.

13.

Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation.

Köberle B, Roginskaya V, Zima KS, Masters JR, Wood RD.

Mol Carcinog. 2008 Aug;47(8):580-6. doi: 10.1002/mc.20418.

PMID:
18240296
14.

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; IALT Bio Investigators.

N Engl J Med. 2006 Sep 7;355(10):983-91.

16.

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.

Bradbury PA, Kulke MH, Heist RS, Zhou W, Ma C, Xu W, Marshall AL, Zhai R, Hooshmand SM, Asomaning K, Su L, Shepherd FA, Lynch TJ, Wain JC, Christiani DC, Liu G.

Pharmacogenet Genomics. 2009 Aug;19(8):613-25. doi: 10.1097/FPC.0b013e32832f3010.

17.

Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.

Mueller T, Mueller LP, Luetzkendorf J, Voigt W, Simon H, Schmoll HJ.

Tumour Biol. 2006;27(2):71-83. Epub 2006 Mar 24.

PMID:
16557044
18.

An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin.

Goldberg Z, Evans J, Birrell G, Brown JM.

Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):175-82.

PMID:
11163512
19.

Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumors.

Honecker F, Mayer F, Stoop H, Oosterhuis JW, Koch S, Bokemeyer C, Looijenga LH.

Lab Invest. 2003 Oct;83(10):1489-95.

PMID:
14563950
20.

Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.

Lan L, Hayashi T, Rabeya RM, Nakajima S, Kanno Si, Takao M, Matsunaga T, Yoshino M, Ichikawa M, Riele Ht, Tsuchiya S, Tanaka K, Yasui A.

DNA Repair (Amst). 2004 Feb 3;3(2):135-43.

PMID:
14706347
Items per page

Supplemental Content

Write to the Help Desk